James F. Oliviero III - SEC Form 4 Insider Trading Activity
Summary
Updated Aug 4, 2026
James F. Oliviero III has filed 1 SEC Form 4 filing across 1 company in the last 90 days - selling. Lifetime open-market sales: $3.07M.
Profile
James F. Oliviero III holds the role of Director at Nuvectis Pharma, Inc. (NVCT). Oliviero's filing history also covers Checkpoint Therapeutics, Inc. (CKPT). Oliviero has reported 3 insider filings with the SEC since 2024. The most recent filing was in June 2026.
| Role | Director |
|---|---|
| Notability | 40/100 |
Board memberships
- Nuvectis Pharma, Inc.
- Checkpoint Therapeutics, Inc.
Reported roles
- Director
- CEO, President and Director
Trading Pattern
InsiderAlpha's records for James F. Oliviero III go back to 2024: 3 primary Form 4 filings, an average of 1.0 per year. No transaction on record carries a Rule 10b5-1 flag - the filings look discretionary rather than pre-scheduled, which makes their timing more informative as a signal.
Career & Filing History
Every role James F. Oliviero III has reported on a Form 4, reconstructed from the filings themselves - reporting insiders must state their relationship to the issuer (officer title, director seat, or 10% ownership) on every filing.
- Director at Nuvectis Pharma, Inc. (NVCT) - 1 filing, 2026
- CEO, President and Director, Director at Checkpoint Therapeutics, Inc. (CKPT) - 2 filings, 2024
Recent Transactions
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-06-12 | NVCT | Nuvectis Pharma, Inc. | A - Grant or award | 35.0K | $0.00 | |
| 2024-12-20 | CKPT | Checkpoint Therapeutics, Inc. | G - Bona-fide gift | 900.0K | $0.00 | |
| 2024-12-20 | CKPT | Checkpoint Therapeutics, Inc. | S - Open-market sale | 220.2K | $3.38 | $744K |
| 2024-12-20 | CKPT | Checkpoint Therapeutics, Inc. | S - Open-market sale | 602.2K | $3.87 | $2.33M |
| 2024-12-17 | CKPT | Checkpoint Therapeutics, Inc. | A - Grant or award | 2.08M | $0.00 |
Companies - Last 90 Days
- Nuvectis Pharma, Inc. (NVCT) - 1 filing, last 2026-06-12
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades at the companies James F. Oliviero III has recently filed at. Multiple unrelated insiders buying the same stock within a short window - cluster buying - has historically been one of the strongest Form 4 signals.
- Marlio Charles Mosseri - $1.87M of NVCT open-market activity in the last 12 months
- Ron Bentsur - $279K of NVCT open-market activity in the last 12 months
- Juan Sanchez - $75K of NVCT open-market activity in the last 12 months
- Matthew L. Kaplan - $64K of NVCT open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
- JANA Partners Management, LP
- Jan Philipp Jenisch
- Marc Johnson
- James Jones
- Andrew T. Kaplan
- A. J. Kazimi
- Michael John Kazley
- Kennedy Lewis Investment Holdings II LLC
Frequently Asked Questions
Who is James F. Oliviero III?
James F. Oliviero III holds the role of Director at Nuvectis Pharma, Inc. (NVCT). Oliviero's filing history also covers Checkpoint Therapeutics, Inc. (CKPT). Oliviero has reported 3 insider filings with the SEC since 2024. The most recent filing was in June 2026.…
How many SEC Form 4 filings has James F. Oliviero III submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Has James F. Oliviero III been buying or selling stock?
Recorded transactions: 0 open-market purchases and 2 open-market sales ($3.07M) across all tracked filings.
Where can I see all of James F. Oliviero III's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Open the live James F. Oliviero III profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.